vs
HomeTrust Bancshares, Inc.（HTB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
HomeTrust Bancshares, Inc.的季度营收约是REGENXBIO Inc.的1.8倍（$53.6M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs 3.7%），HomeTrust Bancshares, Inc.自由现金流更多（$45.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 3.5%）
HomeTrust Bancshares, Inc.是总部位于美国北卡罗来纳州阿什维尔的银行控股公司，总资产达43亿美元，在北卡、南卡、佐治亚和田纳西州共设有33家网点，旗下拥有HomeTrust银行、Tryon联邦银行等七家社区银行。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
HTB vs RGNX — 直观对比
营收规模更大
HTB
是对方的1.8倍
$30.3M
营收增速更快
RGNX
高出39.3%
3.7%
自由现金流更多
HTB
多$98.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
3.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.6M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 37.0% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 3.7% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.93 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HTBRGNX
| Q4 25 | $53.6M | $30.3M | ||
| Q3 25 | $54.1M | $29.7M | ||
| Q2 25 | $54.4M | $21.4M | ||
| Q1 25 | $50.9M | $89.0M | ||
| Q4 24 | $51.7M | $21.2M | ||
| Q3 24 | $50.6M | $24.2M | ||
| Q2 24 | $50.6M | $22.3M | ||
| Q1 24 | $50.0M | $15.6M |
净利润HTBRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $16.5M | $-61.9M | ||
| Q2 25 | $17.2M | $-70.9M | ||
| Q1 25 | $14.5M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $13.1M | $-59.6M | ||
| Q2 24 | $12.4M | $-53.0M | ||
| Q1 24 | $15.1M | $-63.3M |
毛利率HTBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率HTBRGNX
| Q4 25 | 37.0% | -190.0% | ||
| Q3 25 | 38.5% | -176.3% | ||
| Q2 25 | 40.1% | -296.3% | ||
| Q1 25 | 36.2% | 13.6% | ||
| Q4 24 | 35.4% | -242.1% | ||
| Q3 24 | 33.2% | -256.6% | ||
| Q2 24 | 31.3% | -251.3% | ||
| Q1 24 | 38.0% | -408.8% |
净利率HTBRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 30.5% | -208.3% | ||
| Q2 25 | 31.6% | -331.8% | ||
| Q1 25 | 28.5% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 25.9% | -246.3% | ||
| Q2 24 | 24.6% | -237.7% | ||
| Q1 24 | 30.1% | -405.4% |
每股收益（稀释后）HTBRGNX
| Q4 25 | $0.93 | $-1.30 | ||
| Q3 25 | $0.95 | $-1.20 | ||
| Q2 25 | $1.00 | $-1.38 | ||
| Q1 25 | $0.84 | $0.12 | ||
| Q4 24 | $0.83 | $-0.99 | ||
| Q3 24 | $0.76 | $-1.17 | ||
| Q2 24 | $0.73 | $-1.05 | ||
| Q1 24 | $0.88 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $324.7M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $600.7M | $102.7M |
| 总资产 | $4.5B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HTBRGNX
| Q4 25 | $324.7M | $230.1M | ||
| Q3 25 | $315.8M | $274.2M | ||
| Q2 25 | $297.2M | $323.3M | ||
| Q1 25 | $299.8M | $267.9M | ||
| Q4 24 | $279.2M | $234.7M | ||
| Q3 24 | $293.5M | $255.5M | ||
| Q2 24 | $294.2M | $290.4M | ||
| Q1 24 | $380.5M | $338.7M |
股东权益HTBRGNX
| Q4 25 | $600.7M | $102.7M | ||
| Q3 25 | $595.8M | $161.5M | ||
| Q2 25 | $579.3M | $213.7M | ||
| Q1 25 | $565.4M | $274.2M | ||
| Q4 24 | $551.8M | $259.7M | ||
| Q3 24 | $540.0M | $301.4M | ||
| Q2 24 | $523.6M | $348.3M | ||
| Q1 24 | $513.2M | $390.7M |
总资产HTBRGNX
| Q4 25 | $4.5B | $453.0M | ||
| Q3 25 | $4.6B | $525.2M | ||
| Q2 25 | $4.6B | $581.0M | ||
| Q1 25 | $4.6B | $490.9M | ||
| Q4 24 | $4.6B | $466.0M | ||
| Q3 24 | $4.6B | $519.1M | ||
| Q2 24 | $4.7B | $569.4M | ||
| Q1 24 | $4.7B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $45.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 84.5% | -174.0% |
| 资本支出强度资本支出/营收 | 7.8% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $93.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流HTBRGNX
| Q4 25 | $49.5M | $-52.3M | ||
| Q3 25 | $-11.3M | $-56.0M | ||
| Q2 25 | $-8.8M | $-49.3M | ||
| Q1 25 | $71.7M | $33.6M | ||
| Q4 24 | $45.4M | $-31.6M | ||
| Q3 24 | $43.8M | $-40.5M | ||
| Q2 24 | $5.9M | $-45.5M | ||
| Q1 24 | $-9.0M | $-55.5M |
自由现金流HTBRGNX
| Q4 25 | $45.3M | $-52.8M | ||
| Q3 25 | $-12.0M | $-56.5M | ||
| Q2 25 | $-10.2M | $-49.7M | ||
| Q1 25 | $70.7M | $32.6M | ||
| Q4 24 | $42.4M | $-32.7M | ||
| Q3 24 | $43.1M | $-40.9M | ||
| Q2 24 | $5.7M | $-46.0M | ||
| Q1 24 | $-9.6M | $-56.0M |
自由现金流率HTBRGNX
| Q4 25 | 84.5% | -174.0% | ||
| Q3 25 | -22.2% | -189.9% | ||
| Q2 25 | -18.7% | -232.8% | ||
| Q1 25 | 138.7% | 36.6% | ||
| Q4 24 | 82.0% | -154.2% | ||
| Q3 24 | 85.1% | -168.9% | ||
| Q2 24 | 11.2% | -206.2% | ||
| Q1 24 | -19.2% | -358.5% |
资本支出强度HTBRGNX
| Q4 25 | 7.8% | 1.7% | ||
| Q3 25 | 1.4% | 1.7% | ||
| Q2 25 | 2.5% | 1.8% | ||
| Q1 25 | 2.0% | 1.2% | ||
| Q4 24 | 5.9% | 5.1% | ||
| Q3 24 | 1.3% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% | ||
| Q1 24 | 1.1% | 3.6% |
现金转化率HTBRGNX
| Q4 25 | — | — | ||
| Q3 25 | -0.68× | — | ||
| Q2 25 | -0.51× | — | ||
| Q1 25 | 4.93× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.34× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | -0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HTB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
